More than 50% of melanomas are BRAF wild-type, that is, they do not harbor a mutation at the BRAFV600 site. This patient population includes those originating from chronic sun-exposed skin, mucosal, and acral sites. BRAF wild-type melanomas have unique pathophysiologic and prognostic features with significant implications in their therapeutic management. Within this melanoma patient population, there are distinct molecular subsets which may be therapeutically targeted providing additional therapeutic options for these patients. However, thus far there have been no breakthrough targetable genomic alterations in the BRAF wild-type melanoma population that have proven to be consistently efficacious.
ASJC Scopus subject areas